Merus N.V. (MRUS) shares soared 7.1% in the last trading session to close at $44.93. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 6.2% loss over the past four weeks. Last month, the company entered into a collaboration and license agreement with Gilead Sciences to discover novel dual tumor-associated antigens (TAA) targeting trispecific antibodies and develop multiple separate preclinical research programs. This might have dri ...